Despite the availability of genomic testing and new treatments including immunotherapy, cancer outcomes have not changed much over the years. However this may be poised to change. In this panel discussion with representatives from medicine, industry and patient advocacy, we will discuss new molecular testing technologies that are enabling the diagnosis and treatment of solid cancers across all disease stages, impacting patient outcomes and lowering healthcare costs. Dare we hope that cancer may be a chronic disease in the not so distant future?
Ronnie Andrews joined OncoCyte as CEO in July 2019. Prior to this, Ronnie was the founder and principal of the Bethesda Group LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies move emerging diagnostic content and platforms into the marketplace. Ronnie has close to 30 years of experience in the US Clinical and Molecular Diagnostics industry. He served as the President of the Genetic Science Division for Thermo Fisher Scientific until December 2014. Prior to this Ronnie held a number of other high-profile executive roles including CEO of Clarient, a public company on the NASDAQ which was sold to General Electric Healthcare in 2010.
Addressing Key Unmet Needs in Lung Cancer
Please join Ron Andrews President & CEO of Oncocyte as he discusses how Oncocyte is working toward being a novel content aggregator across the Lung Cancer Care Continuum, and solving key clinical questions to better serve patients diagnosed with Lung Cancer.
Bonnie J. Addario, Co-Founder and Board Chair of GO2 Foundation for Lung Cancer (GO2 Foundation) is an advocate and educator empowering patients and giving them a voice since receiving a stage 3B lung cancer diagnosis more than a decade ago. Recognizing the need for education, empowerment, advocacy and research to help patients and families, Bonnie and her family founded the Bonnie J. Addario Lung Cancer Foundation (ALCF) in 2006. In 2019, ALCF and Lung Cancer Alliance joined forces to become GO2 Foundation for Lung Cancer. Bonnie acts as an adviser to patients, industry leaders, clinicians and policy makers and is a member of the Personalized Medicine Coalition board.
Dr. Jablons is a highly accomplished thoracic surgeon, widely sought out by patients in the Bay Area and world-wide. He is also the Director of the Thoracic Oncology Lab, one of the largest in the Department of Surgery, with seven principal investigators, an enviable portfolio of NIH grants, and state-of-art-equipment. Utilizing next-generation sequencing and leveraging one of the largest thoracic tissue banks in the world, the lab has compiled an enviable record of scientific discovery and invention for treatment and lung cancer prevention. Dr. Jablons received his medical degree from Albany Medical College. He completed his general surgery residency at Tufts-New England Medical Center and his thoracic surgery residency at what is now New York Presbyterian-Weill Cornell Medical Center. Dr. Jablons also served as a Navy commander while Chief of Thoracic Surgery at the Oakland Naval Hospital. In 1997, he was named Chief of General Thoracic Surgery at UCSF.
David R. Gandara, MD, Professor of Medicine Emeritus at the University of California at Davis (UC Davis) School of Medicine is the Senior Advisor to the Director, and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). He is an internationally known clinician-scientist and lung cancer thought leader. He has led many notable research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trial through the Southwest Oncology Group (SWOG), and translational science projects. He is the clinical director for a National Cancer Institute (NCI) award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents. He is past chair of the Southwest Oncology Group (SWOG) Lung Committee, and a member and founding co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts and editorials. He is editor-in-chief of the journal Clinical Lung Cancer. He served as president of the International Association for the Study of Lung Cancer (IASLC) from 2009-2011 and served as treasurer from 2013-2017. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). Most recently, he serves as clinical director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer, and is UCD Comprehensive Cancer Center’s principal investigator for the Stand Up To Cancer (SU2C) dream team in KRAS-mutated lung cancer.